Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest

Initial search results include only NCI-sponsored clinical trials. To search all trials, click the "REFINE SEARCH" button, scroll down to the Trial ID/Sponsor section and select the "All" check box in the Sponsor of Trial section.

View Content for:
Display:
?
Drug:  GTI-2040
Find trials that include:  Any drugs shown
Trial Status:  Closed
Results 1-9 of 9 for your search:
Start Over
Phase I/II Study of GTI-2040 and Capecitabine in Patients With Advanced or Metastatic Renal Cell Cancer
Phase: Phase II, Phase I
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: LORUS-L01-1409, NCT00056173
GTI-2040 and Docetaxel in Treating Patients With Recurrent, Metastatic, or Unresectable Locally Advanced Non-Small Cell Lung Cancer, Prostate Cancer, or Other Solid Tumors
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCI-2012-02563, PMH-PHL-017, N01CM17107, CDR0000341677, NCI-6104, 6104, NCT00074022
GTI-2040, Docetaxel, and Prednisone in Treating Patients With Prostate Cancer
Phase: Phase II
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: CDR0000372951, PMH-PHL-024, NCI-6102, 6102, NCT00087165
Combination of GTI 2040 and Cytarabine in the Treatment of Refractory and Relapsed Acute Myeloid Leukemia (AML)
Phase: Phase II
Type: Treatment
Status: Completed
Age: 18 to 60
Sponsor: Pharmaceutical / Industry
Protocol IDs: 2040AML201, NCT00565058
GTI-2040 and Capecitabine in Treating Patients With Metastatic Breast Cancer
Phase: Phase II
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCI-2012-02827, PHII-46, N01CM62209, CDR0000327757, CCC-PHII-46, UCD-200311533-1, CHNMC-PHII-46, NCI-6093, 6093, NCT00068588
GTI-2040 and High-Dose Cytarabine in Treating Patients With Refractory or Relapsed Acute Myeloid Leukemia
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCI-2012-01443, 0304, CDR0000334898, OSU-20030030, NCI-6108, OSU-0304, U01CA076576, 6108, NCT00070551
GTI-2040 and Gemcitabine in Treating Patients With Metastatic or Unresectable Solid Tumors
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCI-2012-02577, 03-06, U01CA069853, CDR0000353204, CTRC-IDD-0306, NCI-6090, 6090, NCT00078962
GTI-2040, Oxaliplatin, and Capecitabine in Treating Patients With Locally Advanced or Metastatic Colorectal Cancer or Other Solid Tumors
Phase: Phase I
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCI-2012-03077, PHI-41, U01CA062505, CDR0000365466, CCC-PHI-41, CHNMC-PHI-41, NCI-6099, 6099, NCT00084643
GTI-2040 in Treating Patients With Relapsed, Refractory, or High-Risk Acute Leukemia, High-Grade Myelodysplastic Syndromes, or Refractory or Blastic Phase Chronic Myelogenous Leukemia
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCI-2009-00206, PHI-57, CDR0000539257, U01CA062505, CCC-PHI-57, 7689, NCT00459212
Start Over